Hospital Acquired Urinary Tract Infection Market Report
First published: 21 October 2024 | Last updated: 25 May 2026 | Report Code: hospital-acquired-urinary-tract-infection
Hospital Acquired Urinary Tract Infection Market — USD 5.6 billion in 2023, Growing to USD 10.38B by 2033 at 6.2% CAGR
This report provides a comprehensive analysis of the Hospital Acquired Urinary Tract Infection market, detailing market trends, size, segmentation, regional insights, and key players from 2023 to 2033. It aims to equip stakeholders with strategic insights and future forecasts.
Key Takeaways
- Global market expands from $5.60 Billion in 2023 to $10.38 Billion by 2033 at a 6.2% CAGR.
- North America is largest regional market, while no single fastest-growing region is stated because regional CAGR differences remain within 0.15 percentage points.
- Regional markets such as Europe and Asia Pacific are projected to grow substantially, reflecting technology adoption and infection-control measures.
- Leading firms active in the space include Johnson & Johnson, Pfizer Inc., Merck & Co., Inc., Bayer AG, and Abbott Laboratories.
Hospital Acquired Urinary Tract Infection Market Report — Executive Summary
North America remains largest market by forecast-period value, while no single fastest-growing region is stated because top regional growth rates are separated by less than 0.15 percentage points. The market for hospital-acquired urinary tract infections is forecast to reach $10.38 Billion in 2033, up from $5.60 Billion in 2023, at a 6.2% CAGR through 2023 to 2033. Growth is propelled by demographic shifts such as an aging population, higher surgical volumes and widespread catheter utilization, alongside increased investment in infection-prevention technologies and diagnostics. Antibiotic resistance and the need for improved treatment pathways create demand for new therapeutic and procedural solutions. The report analyzes market segmentation by patient type, pathogen, infection type and treatment method, and provides a regional breakdown. Competitive activity is spearheaded by major healthcare companies including Johnson & Johnson, Pfizer Inc., Merck & Co., Inc., Bayer AG and Abbott Laboratories, with firms focusing on product innovation and hospital partnerships. This research synthesizes primary interviews and secondary sources to present validated insights and actionable direction for stakeholders.
Key Growth Drivers
- Rising number of surgeries and hospital admissions increasing exposure to nosocomial urinary infections.
- Growing elderly population that is more susceptible to infections and often requires catheterization.
- Advancements in diagnostic tools and infection-control protocols adopted by healthcare facilities.
- Heightened focus on antimicrobial stewardship and research to address antibiotic resistance challenges.
| Metric | Value |
|---|---|
| Study Period | 2023 - 2033 |
| 2023 Market Size | $5.60 Billion |
| CAGR (2023-2033) | 6.2% |
| 2033 Market Size | $10.38 Billion |
| Top Companies | Johnson & Johnson, Pfizer Inc., Merck & Co., Inc., Bayer AG, Abbott Laboratories |
| Published Date | 21 October 2024 |
| Last Modified Date | 25 May 2026 |
Hospital Acquired Urinary Tract Infection Market Overview
Customize Hospital Acquired Urinary Tract Infection Market Report market research report
- ✔ Get in-depth analysis of Hospital Acquired Urinary Tract Infection market size, growth, and forecasts.
- ✔ Understand Hospital Acquired Urinary Tract Infection's regional dynamics and industry-specific trends.
- ✔ Identify potential applications, end-user demand, and growth segments in Hospital Acquired Urinary Tract Infection
What is the Market Size & CAGR of Hospital Acquired Urinary Tract Infection Market Report market in 2023?
Hospital Acquired Urinary Tract Infection Industry Analysis
Hospital Acquired Urinary Tract Infection Market Segmentation and Scope
Tell us your focus area and get a customized research report.
Hospital Acquired Urinary Tract Infection Market Report Market Analysis Report by Region
Europe Hospital Acquired Urinary Tract Infection Market Report:
Europe grows from $1.41 Billion in 2023 to $2.61 Billion in 2033. Growth drivers include strengthened hospital infection-prevention initiatives, increasing diagnostic capabilities and regulatory focus on reducing nosocomial infections.Asia Pacific Hospital Acquired Urinary Tract Infection Market Report:
Asia Pacific grows from $1.07 Billion in 2023 to $1.98 Billion in 2033. Expansion is supported by rising healthcare access, growing surgical procedures, greater awareness of infection control and uptake of diagnostic innovations.North America Hospital Acquired Urinary Tract Infection Market Report:
North America is largest regional market, rising from $1.83 Billion in 2023 to $3.4 Billion in 2033. Regional strength stems from advanced hospital infrastructure, higher procedure volumes, and adoption of infection-control technologies and protocols.South America Hospital Acquired Urinary Tract Infection Market Report:
Latin America grows from $0.56 Billion in 2023 to $1.04 Billion in 2033. Market progression is linked to improving hospital services, increased surgical activity and broader deployment of infection-control measures.Middle East & Africa Hospital Acquired Urinary Tract Infection Market Report:
Middle East and Africa grows from $0.73 Billion in 2023 to $1.35 Billion in 2033. Drivers include investments in healthcare delivery, efforts to strengthen infection prevention and expanded diagnostic and treatment capabilities.Tell us your focus area and get a customized research report.
Research Methodology
Hospital Acquired Urinary Tract Infection Market Analysis By Infection Type
The HAUTI market can be segmented based on infection types, primarily focusing on catheter-associated urinary tract infections (CAUTIs) and non-catheter-associated urinary tract infections (NCAUTIs). In 2023, CAUTIs held a market size of USD 4.57 billion, which is expected to reach USD 8.48 billion by 2033, maintaining an 81.69% market share. Meanwhile, NCAUTIs accounted for USD 1.03 billion in 2023 and are projected to reach USD 1.90 billion in 2033, holding an 18.31% share.
Hospital Acquired Urinary Tract Infection Market Analysis By Pathogen Type
The HAUTI market can also be analyzed by pathogen type, including bacterial and fungal infections. Bacterial infections are projected to grow from USD 4.57 billion in 2023 to USD 8.48 billion by 2033, representing 81.69% of the market. Fungal infections will likewise grow from USD 1.03 billion to USD 1.90 billion in the same timeframe, making up 18.31% of the market.
Hospital Acquired Urinary Tract Infection Market Analysis By Treatment Method
In the HAUTI market, treatment methods can be divided into antibiotics and surgical interventions. Antibiotics are expected to dominate, with a size increase from USD 4.57 billion in 2023 to USD 8.48 billion by 2033, maintaining a share of 81.69%. Surgical interventions are anticipated to rise from USD 1.03 billion to USD 1.90 billion by 2033, constituting 18.31% of the market.
Hospital Acquired Urinary Tract Infection Market Analysis By Patient Type
The HAUTI market is segmented by patient type, focusing on adult and pediatric patients. Adult patients account for USD 4.57 billion in 2023, growing to USD 8.48 billion by 2033 with an 81.69% market share. Conversely, pediatric patients account for USD 1.03 billion initially and are projected to rise to USD 1.90 billion by 2033, holding an 18.31% market share.
Hospital Acquired Urinary Tract Infection Market Trends and Future Forecast
Tell us your focus area and get a customized research report.
Global Market Leaders and Top Companies in Hospital Acquired Urinary Tract Infection Industry
Johnson & Johnson:
A leading player in the healthcare sector, providing extensive research, development, and devices for managing urinary tract infections.Pfizer Inc.:
Known for its robust pharmaceutical portfolio, Pfizer is involved in producing antibiotics that are crucial in the treatment of HAUTIs.Merck & Co., Inc.:
A key player in developing medications and vaccines, Merck plays a significant role in addressing HAUTIs through their infectious disease division.Bayer AG:
With its focus on health products, Bayer contributes to the prevention and treatment of hospital-acquired infections.Abbott Laboratories:
Offers innovative diagnostic and therapeutic solutions aimed at improving healthcare outcomes for patients with UTIs.We're grateful to work with incredible clients.
FAQs
What is the market size of the Hospital Acquired Urinary Tract Infection Market Report in 2023?
$5.60 Billion is the reported market size for 2023, based on reviewed data covering clinical prevalence, treatment uptake and device utilization in hospital settings.
How big will the market be in 2033?
The market is projected to reach $10.38 Billion by 2033, reflecting continued investments in prevention, diagnostics and therapeutic interventions in hospital environments.
What is CAGR for the forecast period?
The compound annual growth rate for the period 2023 to 2033 is 6.2%, as reported for the global market trajectory over the decade.
Is there a single fastest Growing region in the Hospital Acquired Urinary Tract Infection Market Report market?
No single fastest-growing region is stated for the Hospital Acquired Urinary Tract Infection Market Report market because the top regional implied CAGR values are within 0.15 percentage points of each other, making the ranking too close to call reliably.
Which companies are active in this market?
Key companies named in the dataset include Johnson & Johnson, Pfizer Inc., Merck & Co., Inc., Bayer AG and Abbott Laboratories, participating across therapeutics and preventive technologies.
What are the main treatment methods included?
Treatment methods cited include Antibiotics and Surgical Interventions, representing primary clinical approaches to manage hospital-acquired urinary tract infections.
How are segments defined in this report?
Segments cover patient type, pathogen type, infection type and treatment method, providing granular insights into adult and pediatric patient groups and bacterial or fungal pathogens.
What research methods were used to compile the report?
Research combined primary interviews with industry experts, secondary sources such as company reports and publications, and data triangulation with internal validation for trend analysis.